Amryt Pharma plc
http://www.amrytpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amryt Pharma plc
Chiesi Takes Long View To Build Japan Rare Disease Presence
After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances.
Sweden’s Egetis Catches The Eye Of Suitors
With an EU submission imminent for its MCT8 deficiency therapy Emcitate, Egetis is in talks with “certain external partners” about an acquisition.
Chiesi Returns To Respiratory Roots With Affibody Pact
A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.
Stock Watch: J.P. Morgan Conference, Big Splash News And Stock Prices
Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Aegerion Pharmaceuticals, Inc.
- Amryt Pharma Holdings Limited
- Birken GmbH
- Birken AG
- Chiasma, Inc.
- Sompharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice